Spinal muscular atrophy (SMA) was added to the Recommended Uniform Screening Panel (RUSP) in July 2018, following FDA approval of the first effective SMA treatment, and demonstration of feasibility of high-throughput newborn screening using a primary molecular assay. SMA newborn screening was implemented in New York State (NYS) on 1 October 2018.
Screening was conducted using DNA extracted from dried blood spots with a multiplex real-time quantitative polymerase chain reaction (qPCR) assay targeting the recurrent SMN1 exon 7 gene deletion.
During the first year, 225,093 infants were tested. Eight screened positive, were referred for follow-up, and confirmed to be homozygous for the deletion. Infants with two or three copies of the SMN2 gene, predicting more severe, earlier-onset SMA, were treated with antisense oligonucleotide and/or gene therapy. One infant with ≥4 copies SMN2 also received gene therapy.
Newborn screening permits presymptomatic SMA diagnosis, when treatment initiation is most beneficial. At 1 in 28,137 (95% confidence interval [CI]: 1 in 14,259 to 55,525), the NYS SMA incidence is 2.6- to 4.7-fold lower than expected. The low SMA incidence is likely attributable to imprecise and biased estimates, coupled with increased awareness, access to and uptake of carrier screening, genetic counseling, cascade testing, prenatal diagnosis, and advanced reproductive technologies.
Subscribe to Journal
Get full journal access for 1 year
only $41.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Prior TW, Leach ME. Finanger E. Spinal muscular atrophy. In: Adam MP, Ardinger HH, Pagon RA et al., editors. GeneReviews. Seattle, WA: University of Washington; 1993–2019.
Zerres K, Rudnik-Schöneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52:518–523.
Sugarman EA, Nagan N, Zhu H, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72 400 specimens. Eur J Hum Genet. 2012;20:27–32.
Ogino S, Leonard DGB, Rennert H, Ewens WJ, Wilson RB. Genetic risk assessment in carrier testing for spinal muscular atrophy. Am J Med Genet. 2002;110:301–307.
Emery AEH. Population frequencies of inherited neuromuscular diseases—a world survey. Neuromuscul Disord. 1991;1:19–29.
Lin CW, Kalb SJ, Yeh WS. Delay in diagnosis of spinal muscular atrophy: a systematic literature review. Pediatr Neurol. 2015;53:293–300.
Pyatt RE, Prior TW. A feasibility study for the newborn screening of spinal muscular atrophy. Genet Med. 2006;8:428–437.
Kraszewski JN, Kay DM, Stevens CF, et al. Pilot study of population-based newborn screening for spinal muscular atrophy in New York state. Genet Med. 2018;20:608–613.
Chiriboga CA. Nusinersen for the treatment of spinal muscular atrophy. Expert Rev Neurother. 2017;17:955–962.
De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019;29:842–856.
Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713–1722.
Vogel BH, Bonagura V, Weinberg GA, et al. Newborn screening for SCID in New York State: experience from the first two years. J Clin Immunol. 2014;34:289–303.
Cure SMA. Newborn screening for SMA. https://www.curesma.org/newborn-screening-for-sma/. Accessed 5 March 2020.
Glascock J, Sampson J, Haidet-Phillips A, et al. Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening. J Neuromuscul Dis. 2018;5:145–158.
Prior T. Carrier screening for spinal muscular atrophy. Genet Med. 2008;10:840–842.
Committee on Genetics. Committee opinion no. 691: carrier screening for genetic conditions. Obstet Gynecol. 2017;129:e41–e55.
Martin JA, Hamilton BE, Osterman MJK, Driscoll AK, Drake P. Births: final data for 2017. Natl Vital Stat Rep. 2018;67:1–50.
Hendrickson BC, Donohoe C, Akmaev VR, et al. Differences in SMN1 allele frequencies among ethnic groups within North America. J Med Genet. 2009;46:641–644.
Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy—a literature review. Orphanet J Rare Dis. 2017;12:1–15.
Wilson RB, Ogino S. Carrier frequency of spinal muscular atrophy. Lancet. 2008;372:1542.
Ogino S, Wilson RB, Gold B. New insights on the evolution of the SMN1 and SMN2 region: simulation and meta-analysis for allele and haplotype frequency calculations. Eur J Hum Genet. 2004;12:1015–1023.
Orsini JJ, Kay DM, Saavedra-Matiz CA, et al. Newborn screening for Krabbe disease in New York State: the first eight years’ experience. Genet Med. 2016;18:239–248.
Chien YH, Chiang SC, Weng WC, et al. Presymptomatic diagnosis of spinal muscular atrophy through newborn screening. J Pediatr. 2017;190:124–129.e1.
Kariyawasam DST, Russell JS, Wiley V, Alexander IE, Farrar MA. The implementation of newborn screening for spinal muscular atrophy: the Australian experience. Genet Med. 2020;22:557–565.
Vill K, Kölbel H, Schwartz O, et al. One year of newborn screening for SMA—results of a German pilot project. J Neuromuscul Dis. 2019;6:503–515.
Czibere L, Burggraf S, Fleige T, et al. High-throughput genetic newborn screening for spinal muscular atrophy by rapid nucleic acid extraction from dried blood spots and 384-well qPCR. Eur J Hum Genet. 2020;28:23–30.
Glascock J, Sampson J, Connolly A, et al. Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening who have 4 copies of SMN2. J Neuromuscul Dis. 2020;7:97–100
Funding for universal screening was provided by the Centers for Disease Control and Prevention (CDC) (6 NU88EH001319–01–01) and the New York State Department of Health. Funding for the SMA pilot study and validation of the assay for universal screening was provided by Biogen, Idec to Columbia University Medical Center and contracted to the Wadsworth Center. The funding bodies had no role in the design of the study, collection and analysis of data or decision to publish. The authors thank New York State Newborn Screening Program staff, especially Jason Isabelle, Allison Madole, Robert Sicko, and Erin Hughes for technical support and data collection; Neuromuscular Disease Specialty Care Center staff, especially Katherine Hogan, Natasha Kleiman, Jacqueline Gomez, Dr. Angela Pena, Chelsea Kois, Dr. Chin-To Fong, Theresa Harte, Debra Guntrum, and Dawn Dawson; and Erin Collins and Joan Mountain for administrative support.
D.M.K.'s work has been funded by the CDC and Biogen, Idec. C.F.S.'s work has been funded by the CDC and Biogen, Idec. W.K.C.'s work has been funded by the NIH, Simons Foundation, JPB Foundation, and Biogen, Idec. She is on the scientific advisory board for the Regeneron Genetics Center. C.A.C. has received funding from Avexis, Biogen and Roche. She is a consultant (advisory board) for Cytokinetics, Avexis, Genentech, and Roche, and she is an educational speaker for Biogen. E.C. has received personal compensation for serving on advisory boards and/or as a consultant for Avexis, Biogen, Medscape, Pfizer, PTC Therapeutics, Sarepta Therapeutics, Ra Pharma, Wave, and Strongbridge Biopharma. She has received personal compensation for serving on a speaker’s bureau for Biogen and has received research and/or grant support from the CDC, CureSMA, Muscular Dystrophy Association, National Institutes of Health, the Patient-Centered Outcomes Research Institute, Parent Project Muscular Dystrophy, PTC Therapeutics, Santhera, Sarepta Therapeutics, Orphazyme, and the US Food and Drug Administration. She has received royalties from Oxford University Press and compensation from Medlink for editorial duties. B.H.L. receives research support from Sanofi Genzyme. A.S. has received compensation for advisory board consultation for Avexis, Biogen, PTC Therapeutics, and BioMarin. M.C.'s work has been funded by the CDC and Biogen, Idec. The other authors declare no conflicts of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kay, D.M., Stevens, C.F., Parker, A. et al. Implementation of population-based newborn screening reveals low incidence of spinal muscular atrophy. Genet Med 22, 1296–1302 (2020). https://doi.org/10.1038/s41436-020-0824-3
- spinal muscular atrophy (SMA)
- newborn screening (NBS)
- Recommended Uniform Screening Panel (RUSP)
- carrier screening
CMAP changes upon symptom onset and during treatment in spinal muscular atrophy patients: lessons learned from newborn screening
Genetics in Medicine (2020)
International Journal of Neonatal Screening (2020)
Correspondence on: “Discrepancy in Spinal Muscular Atrophy Incidence findings in newborn screening programs: the influence of carrier screening?” by Kay et al
Genetics in Medicine (2020)